December 10, 2019
Ono Pharmaceutical’s BTK inhibitor tirabrutinib delivered an overall response rate (ORR) of nearly 90% in a Japan PII study covering patients with Waldenstrom macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LPL) - types of B cell malignancies, according to the latest data...read more